Published in Contemp Clin Trials on September 10, 2008
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis (EASYBEinNASH) | NCT03198572
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology (2010) 3.73
Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci (2010) 3.72
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (2012) 2.10
Ethnicity and nonalcoholic fatty liver disease. Hepatology (2012) 1.98
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology (2013) 1.77
Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am (2010) 1.51
Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance. Dig Dis Sci (2011) 1.16
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2013) 1.12
Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol (2010) 1.11
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology (2013) 1.10
Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci (2010) 1.05
Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2010) 1.03
Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. Dig Dis Sci (2017) 0.98
Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int (2013) 0.97
Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. J Diabetes Complications (2009) 0.96
Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des (2013) 0.95
Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am (2016) 0.90
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr (2012) 0.89
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care (2015) 0.88
Non-alcoholic fatty liver disease in 2015. World J Hepatol (2015) 0.88
Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol (2014) 0.87
Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2014) 0.84
Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol (2015) 0.83
A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology (2016) 0.82
Pathophysiology guided treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol (2012) 0.82
Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol (2015) 0.80
Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol (2016) 0.77
Hepatic fat during fasting and refeeding by MRI fat quantification. J Magn Reson Imaging (2014) 0.76
Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology (2016) 0.76
Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease. Open Cardiovasc Med J (2012) 0.76
PharmGKB summary: very important pharmacogene information for CYP4F2. Pharmacogenet Genomics (2015) 0.75
Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep (2017) 0.75
Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol (2015) 0.75
Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease. Pak J Med Sci (2017) 0.75
Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol (2016) 0.75
Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation. J Nutr (2017) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol (2003) 8.23
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology (1990) 6.53
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet (2007) 5.74
Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med (1999) 5.65
Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology (1994) 5.22
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2003) 4.05
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 4.01
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Designs for group sequential tests. Control Clin Trials (1984) 3.56
Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology (2003) 3.51
Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med (2000) 3.47
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology (2002) 3.29
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr (2000) 2.88
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol (2001) 2.81
Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis (2001) 2.63
Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis (2001) 2.56
Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol (1989) 2.26
Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology (2007) 2.22
Update on nonalcoholic fatty liver disease. J Clin Gastroenterol (2002) 2.20
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology (1998) 2.19
Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut (2004) 2.15
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther (2001) 1.73
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology (2003) 1.19
Safety of oral intake of vitamin E. Am J Clin Nutr (1988) 1.09
Use and safety of elevated dosages of vitamin E in adults. Int J Vitam Nutr Res Suppl (1989) 0.84
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med (2000) 8.32
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med (2012) 3.51
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol (2007) 2.98
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology (2012) 2.93
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Sepsis-induced cholestasis. Hepatology (2007) 2.80
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology (2004) 2.64
Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med (2008) 2.61
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology (2010) 2.48
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology (2011) 2.30
Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology (2010) 2.30
Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 2.28
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl (2002) 2.25
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology (2009) 2.16
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol (2011) 2.15
Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Gastrointest Endosc (2006) 2.14
Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology (2008) 2.10
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (2012) 2.10
Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol (2011) 2.09
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr (2007) 1.99
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol (2009) 1.93
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (2013) 1.92
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch (2007) 1.91
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology (2007) 1.90
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol (2011) 1.88
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87